What was filed
Venus Remedies' board met on 26 October 2026 and approved unaudited standalone and consolidated results for the quarter and half-year ended 30 September 2026, with the statutory auditor's limited review report. The company operates in a single reportable segment, "Pharmaceuticals", and consolidates two overseas units — wholly owned Venus Pharma GmbH in Germany and its step-down subsidiary Venus Pharma Kft in Hungary.
The quarter in brief
On a standalone basis, revenue from operations and net profit both rose versus the June quarter and the year-ago September quarter, per the filing; the figures are in the panel below. The consolidated picture is more mixed: group net profit for the quarter came in below the standalone figure, reflecting losses at the German operation. The auditor's "other matter" note records that Venus Pharma GmbH contributed revenue of INR 3.64 crore and a net loss to the group for the period, while Venus Pharma Kft was nil.
The German subsidiary note
The auditor included an emphasis-of-matter paragraph — which does not modify the review conclusion — on share application money relating to Venus Pharma GmbH, for which formal share allotment remains pending. Management represented that allotment is not mandatory under German law, that it considers the investment strategic, and that it intends to recover the amount through a restructuring of European operations carried out in FY 2026-27. The company stated the subsidiary is currently facing financial challenges and reiterated its intention to provide financial and operational support during the transition, and that a Germany-based financial consultancy has been engaged to advise on the framework. Separately, the company noted it reviewed the useful life of its intellectual property under Ind AS 38, raising depreciation and amortisation for the period.